Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2010 1
2011 4
2012 6
2013 5
2014 4
2015 4
2016 2
2017 4
2019 3
2020 4
2021 5
2022 7
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R. Narita Y, et al. Among authors: yonezawa h. Neuro Oncol. 2021 Jan 30;23(1):122-133. doi: 10.1093/neuonc/noaa145. Neuro Oncol. 2021. PMID: 32583848 Free PMC article. Clinical Trial.
Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.
Arakawa Y, Narita Y, Nagane M, Mishima K, Terui Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Aoi A, Nishikawa R. Arakawa Y, et al. Among authors: yonezawa h. Neurooncol Adv. 2023 Sep 14;5(1):vdad109. doi: 10.1093/noajnl/vdad109. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37744697 Free PMC article.
Alterations in EGFR and PDGFRA are associated with the localization of contrast-enhancing lesions in glioblastoma.
Makino R, Higa N, Akahane T, Yonezawa H, Uchida H, Takajo T, Fujio S, Kirishima M, Hamada T, Yamahata H, Kamimura K, Yoshiura T, Yoshimoto K, Tanimoto A, Hanaya R. Makino R, et al. Among authors: yonezawa h. Neurooncol Adv. 2023 Sep 2;5(1):vdad110. doi: 10.1093/noajnl/vdad110. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37744696 Free PMC article.
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
Yamamoto M, Sanomachi T, Suzuki S, Uchida H, Yonezawa H, Higa N, Takajo T, Yamada Y, Sugai A, Togashi K, Seino S, Okada M, Sonoda Y, Hirano H, Yoshimoto K, Kitanaka C. Yamamoto M, et al. Among authors: yonezawa h. Neuro Oncol. 2021 Jun 1;23(6):945-954. doi: 10.1093/neuonc/noab015. Neuro Oncol. 2021. PMID: 33556172 Free PMC article.
Pilocytic Astrocytoma Presenting with Spontaneous Cerebellar Hemorrhage: A Case Report.
Yamanaka S, Tokimura H, Higa N, Iwamoto H, Nishimuta Y, Sueyoshi K, Yonezawa H, Tajitsu K, Akahane T, Tanimoto A, Hanaya R. Yamanaka S, et al. Among authors: yonezawa h. NMC Case Rep J. 2023 Oct 14;10:303-308. doi: 10.2176/jns-nmc.2023-0152. eCollection 2023. NMC Case Rep J. 2023. PMID: 37953905 Free PMC article.
Differentiating primary central nervous system lymphoma from glioblastoma by time-dependent diffusion using oscillating gradient.
Kamimura K, Nakano T, Hasegawa T, Nakajo M, Yamada C, Kamimura Y, Akune K, Ejima F, Ayukawa T, Nagano H, Takumi K, Nakajo M, Higa N, Yonezawa H, Hanaya R, Kirishima M, Tanimoto A, Iwanaga T, Imai H, Feiweier T, Yoshiura T. Kamimura K, et al. Among authors: yonezawa h. Cancer Imaging. 2023 Nov 30;23(1):114. doi: 10.1186/s40644-023-00639-7. Cancer Imaging. 2023. PMID: 38037172 Free PMC article.
49 results